Comparing the costs and benefits of the use of an mRNA HR-HPR assay to a DNA HR-HPV assay in the proposed cervical screening programme in France
Cervical cancer is the fourth most common cancer in women aged 15 to 44 years in France. With the implementation of cytology-based cervical screening, cervical cancer incidence and mortality have decreased over time, however, cervical cancer remains a concern. As cervical cancer is primarily caused by persistent infection with high-risk human papillomaviruses (HR-HPV), guidelines for Read More >